Lakhasly

reported MTA-based zinc oxide eugenol may serve as a safe substitute to FC for pulpotomies on cariously exposed primary molars.Formocresol and zinc oxide eugenol are in Group A, while MTA-based zinc oxide eugenol is in Group B. Clinical evaluations were conducted on 1, 3, 6, and 9 months, radiographic evaluations on 6 and 12 months, and pain assessments were conducted at 0, 1, 3, and 7 days.With reference to group B (zinc oxide eugenol based on MTA): always, the MTA group demonstrated no pain, with a 100% success rate in terms of pain evaluation.Twenty kids between the ages of four and seven needed pulpotomy utilizing the split mouth approach.

reported MTA-based zinc oxide eugenol may serve as a safe substitute to FC for pulpotomies on cariously exposed primary molars. Twenty kids between the ages of four and seven needed pulpotomy utilizing the split mouth approach. Formocresol and zinc oxide eugenol are in Group A, while MTA-based zinc oxide eugenol is in Group B. Clinical evaluations were conducted on 1, 3, 6, and 9 months, radiographic evaluations on 6 and 12 months, and pain assessments were conducted at 0, 1, 3, and 7 days. After the third day, none of the patients in group A (Formocresol/zinc oxide eugenol) reported any pain, according to the pain evaluation. After three days, the FC group shows a 100% success rate. Between the third and seventh days, there was no discernible difference between the two groups. At the end of nine months, FC had a clinical success rate of 85%, whereas at the end of twelve months, radiographic success was 65%. With reference to group B (zinc oxide eugenol based on MTA): always, the MTA group demonstrated no pain, with a 100% success rate in terms of pain evaluation. The clinical success rate for the MTA group was 100% at the end of nine months, whereas the radiographic examination at the end of twelve months indicated an 85% success rate.